ArticleHepatology international2012
Natural history of HCV infection.
Article in Hepatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05146609 (Acceptance of Hepatitis C Screening by Self-testing in High Risk and General Population), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Acceptance of Hepatitis C Screening by Self-testing in High Risk and General Population
Who cites it
6 citing papers in PubMed.
- Hepatitis C-Everything a Primary Care Physician Needs to Know About Diagnosis, Management, and Follow-Up.Journal of clinical medicine · 2025Review
- Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020.World journal of clinical cases · 2022Article
- Comparison of double antigen sandwich and indirect enzyme-linked immunosorbent assay for the diagnosis of hepatitis C virus antibodies.Journal of clinical laboratory analysis · 2020Article
- Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history.World journal of hepatology · 2020Review
- Animal Models Used in Hepatitis C Virus Research.International journal of molecular sciences · 2020Review
- Treatment of hepatitis C virus infection in the future.Clinical and translational medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is much controversy surrounding the natural history of hepatitis C virus (HCV) infection.
aimsThe aim of this review was to review the natural history of HCV infection.
methodsPublished English literature was searched via pubmed and then reviewed.
resultsApproximately, 75-85% of HCV-infected persons will progress to chronic HCV infection. The rate of chronic HCV infection is affected by a person's age, gender, race, and viral immune response. Once chronic HCV infection develops, there are external and host factors that can increase the risk of progression of liver disease. Progression of chronic HCV infection is not linear in time, probably because many cofactors change the rate of development of fibrosis, cirrhosis, and hepatocellular carcinoma. Factors linked with aggressive disease progression include age at infection, duration of infection, heavy alcohol use, co-infections with HIV or hepatitis B virus, male sex, steatosis, insulin resistance (and factors associated with the metabolic syndrome), and host genetics. However, the relative importance of many and varied factors remains uncertain, and further research efforts should be directed toward design of predictive models for effective risk stratification. Interferon-based therapy, particularly among those achieving a sustained virologic response (SVR), is associated with improved fibrosis and inflammation scores, reduced incidence of hepatocellular carcinoma, and prolonged life expectancy.
conclusionsDespite the progress in understanding the factors affecting the natural history of HCV infection, a great deal remains to be learnt.
Indexed as
Identifiers
26201520What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.